Sema4 Holdings Corp. (SMFR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sema4 Holdings Corp. (SMFR) trades at $0.3106 with AI Score 60/100 (Grade B+). Sema4 Holdings Corp. Market cap: $246M, Sector: Healthcare.
Price as of Jul 24, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for SMFR: SMFR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SMFR against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SMFR: 1/3 scored disciplines lean bullish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sema4 Holdings Corp. (SMFR) Healthcare & Pipeline Overview
Sema4 Holdings Corp. (SMFR) is a health information company providing AI-driven insights and advanced sequencing services. Its Centrellis platform supports biopharma in drug discovery and development, while Sema4 Signal offers precision oncology care. The company also provides various genetic testing solutions, operating within the competitive healthcare information services sector.
What Is the Investment Thesis for SMFR?
Sema4 Holdings Corp. presents a compelling, albeit high-risk, investment thesis centered on its AI-driven health intelligence platform, Centrellis, and its comprehensive suite of genomic testing services. The company's gross margin of 68.5% indicates strong pricing power and efficient service delivery. Growth catalysts include expanding partnerships with biopharmaceutical companies and increasing adoption of precision oncology solutions. However, the company's negative P/E ratio of -96.58 and negative profit margin of -4.9% highlight significant profitability challenges. Successful execution of its growth strategies and a clear path to profitability are crucial for realizing long-term shareholder value. Investors should closely monitor the company's ability to manage costs and scale its operations effectively.
Based on FMP financials and quantitative analysis
SMFR Key Highlights
- Market Cap of $246M reflects its current valuation in the healthcare information services sector.
- Gross Margin of 68.5% indicates strong pricing power and efficient service delivery.
- P/E Ratio of -96.58 highlights current unprofitability, requiring careful monitoring of future earnings.
- Profit Margin of -4.9% indicates the need for improved cost management and revenue scaling.
- AI-driven Centrellis platform offers potential for significant growth in biopharma partnerships.
Who Are SMFR's Competitors?
SMFR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CATB Catabasis Pharmaceuticals, Inc. | $8.54 | -6.97% | $235M | 45 |
| CELU Celularity Inc. | $0.76 | -2.56% | $18.3M | — |
| INZY Inozyme Pharma, Inc. | $4.00 | +0.25% | $258M | 44 |
| LFCR Lifecore Biomedical, Inc. | $4.43 | -3.28% | $166M | — |
| MGRM Monogram Orthopaedics, Inc. | $6.00 | -1.80% | $244M | 38 |
| DLHTF Dialogue Health Technologies Inc. | $3.79 | +0.59% | $255M | 56 |
| SPOK Spok Holdings, Inc. | $10.46 | -1.74% | $219M | 83 |
| VHIBF Vitalhub Corp. | $4.63 | -2.53% | $293M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SMFR's Key Strengths?
- Proprietary AI-driven Centrellis platform for data analytics.
- Comprehensive suite of genomic testing services.
- Strong relationships with biopharmaceutical companies.
- Expertise in precision oncology and personalized medicine.
What Are SMFR's Weaknesses?
- Negative P/E ratio and profit margin indicate profitability challenges.
- Relatively young company with limited operating history.
- High dependence on partnerships for revenue generation.
- Intense competition in the healthcare information services industry.
What Could Drive SMFR Stock Higher?
- Expansion of partnerships with biopharmaceutical companies to leverage the Centrellis platform.
- Increased adoption of Sema4 Signal for precision oncology care.
- Development and commercialization of new diagnostic tests.
- Geographic expansion into new markets.
What Are the Key Risks for SMFR?
- Financial-distress signal — its Altman Z-Score of -2.16 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-27.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory changes and reimbursement policies affecting genomic testing.
- Technological advancements by competitors leading to market share erosion.
- Economic downturn impacting healthcare spending and investment.
- Data security and privacy breaches compromising sensitive patient information.
- Challenges in achieving profitability and managing costs effectively.
What Are the Growth Opportunities for SMFR?
- Expansion of Biopharma Partnerships: Sema4 can leverage its Centrellis platform to forge deeper partnerships with biopharmaceutical companies, providing them with valuable insights to accelerate drug discovery and development. The biopharmaceutical industry is increasingly relying on data-driven approaches, creating a significant market opportunity for Sema4. By offering comprehensive analytics and advanced sequencing services, Sema4 can become an indispensable partner for biopharma companies seeking to bring new therapies to market faster and more efficiently. This expansion could contribute significantly to revenue growth within the next 2-3 years.
- Increased Adoption of Precision Oncology Solutions: With the growing awareness of personalized medicine, Sema4 can capitalize on the increasing demand for precision oncology solutions. By offering Sema4 Signal, which spans the continuum of cancer care, from prevention to treatment and remission, the company can attract a wider range of healthcare providers and patients. The precision oncology market is projected to reach $42 billion by 2027, presenting a substantial growth opportunity for Sema4. Successful marketing and adoption of Sema4 Signal could drive significant revenue growth over the next 3-5 years.
- Geographic Expansion: Sema4 can expand its geographic reach beyond its current footprint, targeting new markets with unmet needs for advanced genomic sequencing and data analytics. By establishing partnerships with healthcare providers and research institutions in new regions, the company can tap into new revenue streams and diversify its customer base. The global genomics market is expected to reach $62.9 billion by 2028, indicating the potential for significant growth through geographic expansion. This expansion could begin within the next year and contribute to revenue growth over the next 2-4 years.
- Development of New Diagnostic Tests: Sema4 can invest in the development of new diagnostic tests that address emerging healthcare needs, such as early detection of infectious diseases or personalized risk assessment for chronic conditions. By leveraging its expertise in genomic sequencing and data analytics, the company can create innovative tests that provide valuable insights for healthcare providers and patients. The diagnostic testing market is constantly evolving, with new technologies and applications emerging regularly. Successful development and commercialization of new diagnostic tests could drive significant revenue growth over the next 3-5 years.
- Leveraging AI and Machine Learning: Sema4 can further enhance its Centrellis platform by incorporating advanced AI and machine learning algorithms to improve the accuracy and efficiency of its data analytics. By leveraging AI, the company can identify patterns and insights that would be difficult or impossible to detect using traditional methods. This can lead to more personalized and effective healthcare solutions, attracting more customers and driving revenue growth. The AI in healthcare market is projected to reach $45 billion by 2026, highlighting the potential for significant growth through AI-driven innovation. This ongoing development will continuously improve Sema4's offerings.
What Opportunities Does SMFR Have?
- Expansion of biopharma partnerships to accelerate drug discovery.
- Increased adoption of precision oncology solutions.
- Geographic expansion into new markets.
- Development of new diagnostic tests for emerging healthcare needs.
What Threats Does SMFR Face?
- Regulatory changes and reimbursement policies.
- Technological advancements by competitors.
- Economic downturn affecting healthcare spending.
- Data security and privacy concerns.
What Are SMFR's Competitive Advantages?
- Proprietary AI-driven Centrellis platform provides a competitive advantage in data analytics.
- Extensive database of genomic and clinical data enhances the accuracy and insights of its services.
- Strong relationships with biopharmaceutical companies and healthcare providers create barriers to entry.
- Expertise in genomic sequencing and data analytics provides a technological edge.
What Does SMFR Do?
Sema4 Holdings Corp., operating as Sema4, was founded in 2020 and is headquartered in Stamford, Connecticut. The company focuses on transforming healthcare through data-driven insights, offering a comprehensive suite of services designed to enhance the diagnosis, treatment, and prevention of disease. At the core of Sema4's offerings is Centrellis, an AI-driven health intelligence platform that provides biopharmaceutical companies with actionable insights to accelerate drug discovery, development, and commercialization. This platform supports analytics, pre-clinical and clinical trial support, and advanced sequencing services. Sema4 also provides Sema4 Signal, a precision oncology solution that spans the continuum of cancer care, from prevention to treatment and remission. This includes advanced testing for carrier screening, noninvasive prenatal testing, newborn screening, and hereditary cancer testing. Additionally, Sema4 offers COVID-19 testing solutions, demonstrating its ability to quickly adapt to emerging healthcare needs. The company's integrated approach combines advanced genomic sequencing with sophisticated data analytics to deliver personalized and proactive healthcare solutions, positioning it as a key player in the evolving healthcare information landscape.
What Products and Services Does SMFR Offer?
- Provides the Centrellis AI platform for biopharma to accelerate drug discovery.
- Offers advanced sequencing services for research and clinical applications.
- Delivers Sema4 Signal for precision oncology care, from prevention to remission.
- Conducts testing for carrier screening, noninvasive prenatal testing, and newborn screening.
- Performs hereditary cancer testing to assess individual risk.
- Provides COVID-19 testing solutions.
How Does SMFR Make Money?
- Generates revenue through subscription fees for access to the Centrellis platform.
- Earns revenue from providing advanced sequencing services to biopharma and research institutions.
- Receives payments for Sema4 Signal precision oncology testing and services.
- Collects fees for genetic testing, including carrier screening and prenatal testing.
What Industry Does SMFR Operate In?
Sema4 operates within the rapidly evolving healthcare information services industry, which is experiencing significant growth driven by the increasing adoption of AI and genomic sequencing technologies. The market is characterized by intense competition, with companies like CareDx and Exact Sciences vying for market share. The industry is also influenced by regulatory changes, reimbursement policies, and technological advancements. Sema4's focus on precision oncology and biopharma partnerships positions it to capitalize on the growing demand for personalized medicine and data-driven healthcare solutions. The global healthcare analytics market is projected to reach $75 billion by 2026, presenting substantial growth opportunities for companies like Sema4.
Who Are SMFR's Key Customers?
- Biopharmaceutical companies seeking to accelerate drug discovery and development.
- Healthcare providers offering precision oncology care to their patients.
- Individuals seeking genetic testing for carrier screening, prenatal testing, or cancer risk assessment.
- Research institutions conducting genomic research.
Company Profile
Sema4 Holdings Corp. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Stamford, US. The company is led by CEO Jason Ryan. SMFR has traded publicly since 2020.
How Sema4 Holdings Corp. Is Valued
Sema4 Holdings Corp. carries a market capitalization of $246M, placing it in the micro-cap category. Relative to its peer group, SMFR's quantitative score of 60/100 is above the peer average of 42/100.
ROE -28%Key Financial Metrics
Return on equity for Sema4 Holdings Corp. stands at -27.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Sema4 Holdings Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.16 places it in the distress zone, a signal of elevated financial risk.
SMFR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary AI-driven Centrellis platform for data analytics.
- Comprehensive suite of genomic testing services.
- Strong relationships with biopharmaceutical companies.
- Expertise in precision oncology and personalized medicine.
Bear Case
- Negative P/E ratio and profit margin indicate profitability challenges.
- Relatively young company with limited operating history.
- High dependence on partnerships for revenue generation.
- Intense competition in the healthcare information services industry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SMFR Latest News
No recent news available for SMFR.
SMFR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SMFR.
Price Targets
Wall Street price target analysis for SMFR.
SMFR MoonshotScore
What does this score mean?
The MoonshotScore rates SMFR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jason Ryan
CEO
Jason Ryan is the CEO of Sema4 Holdings Corp. He brings extensive experience in the healthcare and technology sectors to his role. Prior to joining Sema4, Ryan held leadership positions at several prominent healthcare companies, where he focused on driving innovation and improving patient outcomes. His background includes a strong track record in strategic planning, business development, and operational execution. Ryan's expertise spans various areas of healthcare, including diagnostics, genomics, and data analytics.
Track Record: Since assuming the role of CEO, Jason Ryan has focused on streamlining Sema4's operations and expanding its partnerships with biopharmaceutical companies. Key achievements under his leadership include the continued development of the Centrellis platform and the expansion of Sema4's precision oncology offerings. Ryan has also emphasized the importance of data security and privacy, ensuring that Sema4 adheres to the highest standards of compliance. His strategic decisions have aimed at positioning Sema4 as a leader in the healthcare information services industry.
Common Questions About SMFR (Healthcare)
What does the AI Score mean for SMFR?
SMFR holds an AI Score of 60/100 (Grade: B+). This is an educational research signal, not a buy or sell recommendation. Sema4 Holdings Corp. operates as a health information company, leveraging its AI-driven platform, Centrellis, to enhance disease diagnosis, treatment, and prevention through data-driven insights …
What does Sema4 Holdings Corp. do?
Sema4 Holdings Corp. operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle.
What do analysts say about SMFR stock?
Analyst coverage of Sema4 Holdings Corp. is currently limited, and a consensus rating is not widely available. Key valuation metrics, such as the negative P/E ratio, suggest that the company is not yet profitable. Growth considerations include the potential for increased adoption of the Centrellis platform and expansion of precision oncology services.
What are the main risks for SMFR?
Sema4 Holdings Corp. faces several key risks, including regulatory changes affecting genomic testing, technological advancements by competitors, and economic downturns impacting healthcare spending. The company also faces risks related to data security and privacy, as well as challenges in achieving profitability and managing costs effectively.
What are the key factors to evaluate for SMFR?
Sema4 Holdings Corp. (SMFR) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does SMFR data refresh on this page?
SMFR's price was last updated on Jul 24, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SMFR's recent stock price performance?
Sema4 Holdings Corp. (SMFR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AI-driven Centrellis platform for data analytics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SMFR overvalued or undervalued right now?
Sema4 Holdings Corp. (SMFR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SMFR before investing?
Before investing in Sema4 Holdings Corp. (SMFR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage may impact the accuracy of consensus estimates.
- Future financial performance is subject to various risks and uncertainties.